Efficacy of sodium-glucose cotransporter 2 inhibitors after acute myocardial infarction: Are the benefits limited to patients with diabetes? A systematic review and meta-analysis.
Marcel Catão F Santos, Isadora Mamede, Rodrigo Bessa et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients post-acute myocardial infarction (AMI). Analyzing data from 31,378 patients, the study found significant reductions in heart failure readmissions (OR 0.61), all-cause mortality (OR 0.62), and stroke (OR 0.67) associated with SGLT2 inhibitors, particularly in diabetic and non-STEMI populations. The findings were primarily driven by observational studies.
Key findings
- SGLT2 inhibitors reduced heart failure readmissions (OR 0.61; p < 0.01).
- There was a significant reduction in all-cause mortality (OR 0.62; p < 0.01).
- Stroke incidence was lower in patients using SGLT2 inhibitors (OR 0.67; p < 0.01).
- Benefits were more pronounced in diabetic and non-STEMI patients.
Why it matters
Understanding the potential benefits of SGLT2 inhibitors in post-AMI care is crucial, especially given the high mortality and readmission rates associated with heart failure. This evidence may inform future treatment strategies for specific patient populations.